- The companies signed an agreement with to evaluate VIR-7832 vs PBO in P-Ib/IIa AGILE study in patients with mild to mod. COVID-19. The trial is expected to be initiated in Q1’21 across up to five sites in the UK
- The preclinical data demonstrated that VIR-7832 enhanced ability to clear infected cells and enhance virus-specific T cell function, treating or prevent COVID-19 infection
- VIR-7832 is a dual-action mAb, currently being evaluated in two global P-III studies for the early treatment of COVID-19 in patients who are at high risk of hospitalization, and for hospitalized patients with COVID-19
Click here to read full press release/ article | Ref: GSK | Image: Medical Dialogues
The post GSK and VIR Biotechnology to Evaluate VIR-7832 in the Early Treatment of COVID-19 first appeared on PharmaShots.